SCHEMBL2229263

SCHEMBL2229263

O=C(O)c1ccc(OCc2ccccc2)c(OCc2ccccc2)c1OCc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.57
L3MBTL1 Q9Y468 2/20 0.52
MAPT P10636 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
ALDH1A1 P00352 2/20 0.52
KDM4E B2RXH2 1/20 0.52
POLB P06746 1/20 0.52
PTGER1 P34995 2/20 0.51
MYC P01106 1/20 0.49
MCL1 Q07820 2/20 0.49
CHRM4 P08173 1/20 0.49
CHRM3 P20309 1/20 0.49
CLCN2 P51788 1/20 0.49
CTSV O60911 1/20 0.48
CTSL P07711 1/20 0.48
PTPN1 P18031 1/20 0.48
SGMS2 Q8NHU3 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL514324 0.98 FOLH1 (0.56) FOLH1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL3424839 0.91 ALDH1A1 (0.55) FOLH1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL14882633 0.91 CTSV (0.53) FOLH1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL26021326 0.87 MAPT (0.65) FOLH1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL30184648 0.87 PARP1 (0.54) FOLH1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL9724220 0.87 FOLH1 (0.55) FOLH1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL514323 0.87 L3MBTL1 (0.50) FOLH1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL1305739 0.87 PTGER1 (0.61) FOLH1L3MBTL1MAPTTDP1ALDH1A1
SCHEMBL24983833 0.86 PTGER1 (0.60) FOLH1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL11110377 0.86 MCL1 (0.55) FOLH1L3MBTL1MAPTCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336588-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES, INC. 2024-10-10 US disclosed
CN-118076589-A Amide compound, preparation method and pharmaceutical application thereof 中国科学院上海药物研究所 2024-05-24 CN disclosed
EP-4370113-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS Avanti Biosciences Inc. (US) 2024-05-22 EP disclosed
CN-117794526-A Compositions and methods for antioxidants and anti-inflammatory therapeutics 阿万蒂生物科学股份有限公司 2024-03-29 CN disclosed
WO-2023168240-A1 SMALL MOLECULE INHIBITORS OF ENPP1 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-09-07 WO disclosed
WO-2023288020-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES INC. (US) 2023-01-19 WO disclosed
WO-2023288020-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES INC. (US) 2023-01-19 WO disclosed
WO-2022268145-A1 AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 中国科学院上海药物研究所 2022-12-29 WO disclosed
CN-115504940-A Amide compound, preparation method and pharmaceutical application thereof 中国科学院上海药物研究所 2022-12-23 CN disclosed
EP-2917203-B1 METHOD FOR IDENTIFYING MYC INHIBITORS DANA FARBER CANCER INST INC (US) 2019-04-03 EP disclosed
US-9567301-B2 Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-02-14 US disclosed
US-9370529-B2 Tannin inhibitors of HIV UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2016-06-21 US disclosed
US-20160038520-A1 TANNIN INHIBITORS OF HIV NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2016-02-11 US disclosed
US-8901317-B2 Tryptamine derivatives, their preparation and their use in gastropathy COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-12-02 US disclosed
US-20130197052-A1 TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY UNIVERSITY OF CALCUTTA (IN) 2013-08-01 US disclosed
WO-2011085454-A1 GP120 -BINDING BENZENE COMPOUNDS AND SACCHARIDE COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN K.U.LEUVEN R&D (BE) 2011-07-21 WO disclosed
EP-1171130-A4 PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME GUILFORD PHARM INC (US) 2004-05-19 EP disclosed
EP-1171130-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME GUILFORD PHARMACEUTICALS INC. (US) 2002-01-16 EP disclosed
WO-2000025787-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME GUILFORD PHARMACEUTICALS INC. (US) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336588-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS MPO, GPX4, GPX1 FOLH1 1463/4885L3MBTL1 4489/4885MAPT 1586/4885
US-20130197052-A1 TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY HTRA2, AIFM1, SI FOLH1 2144/4885L3MBTL1 3343/4885MAPT 4040/4885
US-20160038520-A1 TANNIN INHIBITORS OF HIV SERPINB1, TSN, FURIN FOLH1 2739/4885L3MBTL1 3830/4885MAPT 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.